# Urology Referral

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Hubert H. Humphrey (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML022-SYN-TD
- Date: 1977-01-06
- Fictional facility: St. Posthumous Health Center
- Fictional author: Walter Brandvold, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- To: Elaine Kowalczyk, MD, Urology
- Urgency: Routine, within four weeks

## Referral question

Man of 65, three months after radical cystoprostatectomy with an ileal conduit at a cancer center for multifocal urothelial carcinoma with carcinoma in situ, pT2a N0, margins negative. Please share his survivorship surveillance close to home, review his stoma, and set the metabolic monitoring plan. **S**

## Questions for the consultant

1. Is any adjuvant treatment indicated for pT2a N0 disease with negative margins?
2. What surveillance imaging and tests does he need, at what intervals, and which should primary care arrange?
3. How should his appliance leaks and peristomal skin be managed, and which stoma complications should we watch for?
4. What kidney and metabolic monitoring does the ileal conduit need (creatinine, acid-base, vitamin B12), and when should we treat?
5. How should we interpret urine findings with a conduit, and when should infection be treated?
6. Does the remaining urethra need surveillance?

## Pertinent history

Blood in the urine decades ago; small benign bladder growths removed; later, possibly cancerous tissue treated with intravesical thiotepa and five weeks of pelvic radiation. After three years free of disease, cystoscopy for urinary symptoms found recurrent multifocal low-grade papillary tumors with high-grade carcinoma in situ in a small, radiation-affected bladder, and he had an early radical cystoprostatectomy with pelvic node dissection, partial urethrectomy, and an ileal conduit. Final pathology: high-grade urothelial carcinoma invading the inner half of the muscularis propria (pT2a), 0 of 18 nodes, ureteric and urethral margins negative, prostate without urothelial involvement. Pre-operative CT showed no spread. No chemotherapy was given before or after surgery. Recovery uncomplicated; back at full-time work. Creatinine 1.12 mg/dL (eGFR 73), chloride 106, bicarbonate 22 mmol/L, hemoglobin 12.6 g/dL, vitamin B12 412 pg/mL. PHQ-9 score 3. Appliance leaks at night have started in the past week. No regular medicines. Tobacco history not recorded. **S**

- Hubert Horatio Humphrey Jr. was born on 27 May 1911 in Wallace, South Dakota. **D**
- Humphrey served in the U.S. Senate from Minnesota from 1949 to 1964, as vice president from 1965 to 1969, and again in the Senate from 1971 until his death. **D**
- Humphrey sought medical advice in 1967 for blood in his urine; some doctors suspected bladder cancer, others disagreed, and he was not treated. In 1968 doctors found and removed several pinhead-size nonmalignant growths from his bladder. In 1994 researchers reported a p53 gene mutation in bladder cells from a 1967 urine sample of his. **D**
- In 1973 doctors found possibly cancerous tissue in his bladder and treated it with thiotepa and X-ray therapy, given five minutes a day for five weeks. **D**
- After three years free of cancer, an examination at the National Naval Medical Center in Bethesda for symptoms of a urinary tract infection found a low-grade malignancy, and in October 1976 a six-hour radical cystectomy at Memorial Sloan-Kettering Cancer Center removed his bladder, prostate, lymph nodes, the fatty tissue around the bladder, and part of the urethra; the ureters were joined to a conduit made from a segment of small intestine, brought out to an opening on the skin to the right of the navel and drained into a bag. The nodes were to be examined for spread, and an experimental two-drug chemotherapy might be offered. **D**
- He resumed his Senate duties in January 1977, serving as deputy president pro tempore from January 5, 1977. **D**

2 later historical claims are omitted because they describe events after the index age. See the teaching note.

Baseline: Sodium: 139 mmol/L; Potassium: 4.3 mmol/L; Chloride: 106 mmol/L; Bicarbonate (total CO2): 22 mmol/L; Urea nitrogen: 18 mg/dL; Creatinine: 1.12 mg/dL; eGFR: 73 mL/min/1.73 m²; Calcium: 9.2 mg/dL; Albumin: 3.7 g/dL; Alkaline phosphatase: 88 U/L; ALT: 22 U/L; Hemoglobin: 12.6 g/dL (low); White cell count: 6.4 10*3/uL; Platelets: 284 10*3/uL; Vitamin B12: 412 pg/mL; PHQ-9: 3. All results are synthetic.

BP 126/76 mmHg; pulse 74 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 97% on room air; weight 76.5 kg; BMI 23.6 kg/m². All vital signs are synthetic.

## Current medications

- No current medications. **S**

## Plan so far

- Stoma care with the wound, ostomy, and continence nurse: appliance fitting, peristomal skin care, and parastomal hernia checks. Guideline: Holzbeierlein J, et al. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024). J Urol 2024;212(1):3-10 (2024); CMID: Clinical Monitoring Intelligence Database, urologic cancer monograph (2026) **S**
- Distress screening at each visit, physical activity, and a written survivorship care plan. Guideline: NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer (2026); CMID: Clinical Monitoring Intelligence Database, urologic cancer monograph (2026) **S**
